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A b s t r a c t  
A Controlled porosity of the membrane is accomplished by the use of pore former. The usual 
dose of glimepiride was 4 mg to be taken twice daily. The plasma half life of glimepiride was 
5 h. Hence, glimepiride was chosen as a model drug with an aim to develop a controlled 
release system for 24 h. Sodium chloride was use as osmogent. Cellulose acetate was used 
as the semi permeable membrane. The porous osmotic pump contains pore forming water-
soluble additive (Poly ethylene glycol 400) in the coating membrane which after coming in 
contact with water, dissolve, resulting in an in situ formation of microporous structure. The 
effect of different formulation variables, namely, ratio of drug to osmogent, membrane weight 
gain and concentration of pore former on the in vitro release was studied using 23 full 
factorial design. The effect of pH and agitation intensity on drug release was also studied. It 
was found that drug release rate increased with the amount of osmogent because of 
increased water uptake. Drug release was inversely proportional to membrane weight gain. 
Surface plot is also presented to graphically represent the effect of independent variables on 
t90. Optimized formulation was found to release above 90% of glimepiride at a zero order rate 
for 24 h. 
Keywords: Controlled porosity osmotic pump, glimepiride, osmogent, pore former, factorial 
design 
 
Introduction 
In recent years, considerable attention has been focused on the 
development of novel drug delivery systems. Once daily 
controlled release preparation is often desirable. However, drug 
release from oral controlled release dosage forms may be 
affected by pH, gastric motility, and presence of food. One 
practical approach with a potential to overcome these 
disadvantages is the osmotic drug delivery system where osmotic 
material have been used extensively in the fabrication of drug 
delivery systems [1]. 
The historical developments of osmotic systems include seminal 
contributions such as the rose nelson pump, higuchi leeper 
pumps, alzet osmotic pump, elementary osmotic pump and push 
pull osmotic pump. The osmotic drug delivery systems suitable for 
oral administration typically consist of compressed tablet core that 
is coated with a semi permeable membrane that has an orifice 
drilled on it by means of a laser beam. The rate at which the core 
absorbs water depends on the osmotic pressure generated by the 
core components and the permeability of the membrane coating. 
As the core absorbs water, it expands in volume which pushes the  
 
 
drug solution or suspension out of the tablet through one or more 
delivery ports. To obviate the need for complicated laser drilling, 
tablets coated with a membrane of controlled porosity have been 
described. These membranes consist of leachable material which 
dissolves upon contact with water, leaving behind the pores 
through which the drug solution is pumped out. Drug release from 
these systems is independent of pH and hydrodynamic conditions 
of gastro-intestinal tract to a large extent, and release 
characteristics of delivery system [1-3]. 
Glimepiride, an oral hypoglycemic agent, is one of the most 
commonly prescribed drugs for the treatment of patients with type 
II diabetes mellitus. It is practically water-insoluble, but the 
absolute bioavailability is close to 1. Thus, it belongs to class 2 of 
biopharmaceutics classification system. Glimepiride has a 
relatively short elimination half life (5 h), thereby requiring twice 
daily dosing in large number of patients, which often leads to non-
compliance. Thus, there is a strong clinical need and market 
potential for a dosage form that will deliver glimepiride in a 
controlled manner to a patient compliance [4-6]. 
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Materials and Methods 
Materials 
Glimepiride was obtained as gift sample from Zydus cadila, 
Ahmedabad. Micro crystalline cellulose was obtained from FMC 
biopolymers, USA. Cellulose acetate, Acetone, PEG 400, Nacl, 
Magnesium stearate and talc were obtained from S.D. fine 
chemicals, Mumbai. 
Methods 
Drug-excipient compatibility study 
FTIR absorption spectra of pure drug and physical mixture were 
recorded in the range of 400 to 4000 cm-1 by KBr disc method 
using FTIR spectrophotometer [7]. 
 
Experimental design 
A number of preliminary experiments were conducted to 
determine the formulation and parameters by which the process 
resulted in controlled porosity osmotic pump tablets. A full factorial 
23 design was employed for the optimization procedure. The 
drug:osmogent ratio (X1), concentration of pore former (X2) and % 
weight gain (X3) were selected as the independent variables, 
where as t90 i.e. the average time required to release 90 % of 
glimepiride (Y) was chosen as the dependent variables. Table 1 
summarizes these factors with corresponding levels and the 
responses studied, where as experimental formulations are listed 
in Table 2. The factors were selected to measure the change in 
response from one extreme factor to another and for determining 
interactions, if any, among the factors with their best levels for 
optimizing the considered experimental responses [8]. 
 
Preparation core tablets (S1 to S8) 
The formulations SP1 to SP8 were prepared by direct compression 
method. The formulation ingredient quantity was selected as per 
trial and error method. This trial and error method was also 
supported by extensive literature review for nearby optimize 
quantity of each ingredients in this study.  All the ingredients were 
passed through sieve # 60 separately, weighed and mixed in 
geometrical order. Then lubricant and glidant (standard sieve # 
120) were added and mixed for further 5 minute. The resulting 
powder mixtures were then compressed into tablets using a rotary 
tablet machine fitted with 6 mm flat faced punches. Formulae of 
different core formulation (SP1 to SP8) of glimepiride were listed in 
Table 2 [7]. 
 
Preparation of coating solution 
Coating solution was prepared by mixing required quantity of 
cellulose acetate (semi permeable membrane) and PEG 400 
(pore former and plasticizer) in acetone and stirred on magnetic 
stirrer to get homogeneous coating solution. The coating 
composition for glimepiride core formulation was listed in Table 2 
[7]. 
 
Dip coating method 
In the present study, dip coating method was used to coat the 
tablets. The formulations SP1 to SP8 were used as the core 
tablets. The weighed core tablets were dipped into coating 
solutions by holding with forcep and after dipping were placed on 
a glass plate (smeared with PEG 400) for drying in air for 15 
minutes at room temperature. The tablets were then dried at 60ĈC 
in an oven for 30 minutes. During drying, the tablets were rotated 
occasionally. The tablets were subjected to coat about 5 % w/w, 8 
% w/w and 10 % w/w of total weight of tablet [9]. 
Evaluation of controlled porosity osmotic pump tablets 
[10-15] 
Evaluation of powder blend [10-15] 
The flow property of core material ready to compress was 
evaluated by measuring bulk density, tapped density, hausnerÊs 
ratio, carrÊs index and angle of repose. 
 
Evaluation of core tablets [7]   
Tablets were evaluated for hardness by using a Monsanto type 
hardness tester. Friability of the tablets was evaluated by a Roche 
Friabilator (Mumbai, India). Thickness of the tablets was 
measured by using Vernier calipers. 
 
Weight variation 
The tablets were randomly selected from each batch and 
individually weighted. The average weight and standard deviation 
of 20 tablets were calculated. 
 
Content uniformity 
Five tablets were taken and finely powdered. The quantities of the 
powder equivalent to 4 mg of glimepiride were accurately weighed 
and transferred to a 100 ml of volumetric flask. The flask was filled 
with phosphate buffer (pH 7.4) solution and mixed thoroughly. The 
solution was made up to volume and filtered and the absorbance 
of the resulting solution was measured at 228 nm by using UV-
visible double beam spectrophotometer. 
 
In vitro drug release study of factorial design 
formulations (SP1 to SP8) [15] 
In vitro release of glimepiride from factorial design formulations 
was carried out by using USP type II apparatus at a rotation 
speed of 50 rpm and at 37 μ 0.5ĈC using 900 ml phosphate buffer 
pH 7.4 as the dissolution media. At appropriate time intervals, 
dissolution samples were withdrawn and filtered. Samples were 
analyzed at 228 nm by using UV-visible double beam 
spectrophotometer. The amount of glimepiride dissolved in the 
dissolution media was then determined from the calibration curve 
and the cumulative percentage of glimepiride released was 
calculated. 
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Release kinetics 
In order to understand the mechanism and kinetics of drug 
release, the results of the in vitro drug release study were fitted 
with various kinetic equations namely zero order (% release vs t), 
first order (log% unrelease vs t) , higuchi matrix (% release vs 
square root of time). In order to define a model which will 
represent a better fit for the formulation, drug release data further 
analyzed by Korsmeyer Peppas equation, Mt/M¥=ktn, where Mt is 
the amount of drug released at time t and M¥ is the amount 
released at time ¥, the Mt/M¥ is the fraction of drug released at time 
t, k is the kinetic constant and n is the diffusional exponent, a 
measure of the primary mechanism of drug release. R2 values 
were calculated for the linear curves obtained by regression 
analysis of the above plots [16-18]. 
Statistical analysis  
Polynomial models, including interaction terms for all response 
variables using multiple linear regression analysis using Microsoft 
Excel 207. A polynomial model together with interaction terms 
was generated for the response variable (Y) by means of multiple 
linear regression analysis. 3D response plots were constructed 
using sigma plot software. One optimum checkpoint was selected 
by layout grid search techniques, performed over the entire 
experimental domain. Values were predicted for the 
drug:osmogent ratio, concentration of pore former, % weight gain 
using a mathematical model developed for the optimized 
formulation. The formula of checkpoint formulation is shown in 
above Table 3 [6]. These predicted values were compared with 
the resulting experimental values and the percentage bias was 
calculated.  
۰ܑ܉ܛ ሺ% ሻ ൌ
ሺ܍ܠܘ܍ܚܑܕ܍ܖܜ܉ܔ ܞ܉ܔܝ܍ െ ܘܚ܍܌ܑ܋ܜ܍܌ ܞ܉ܔܝ܍ሻ ൈ ૚૙૙
܍ܠܘ܍ܚܑܕ܍ܖܜ܉ܔ ܞ܉ܔܝ܍ 
   
 
To study effect of pH on in vitro drug release 
In order to study the effect of pH of the release media, release 
study of optimized formulation (SP9) were carried out in 
dissolution apparatus USP type II in 0.1 N HCl, phosphate buffer 
pH 6.8, phosphate buffer pH 7.4 medium for 24 h with the 
temperature maintained at 37 μ 0.5 ĈC. Samples of 5 ml were 
withdrawn at specific time intervals, filtered and analyzed at 228 
nm by using UV-visible double beam spectrophotometer. 
To study effect of agitation intensity on in vitro drug 
release 
In order to study the effect of agitation intensity of the release 
media, release study of optimized formulation (SP9) were carried 
out in dissolution apparatus at various rotational speeds. 
Dissolution apparatus used was USP type II at 50, 100, and 150 
rpm for 24 h with the temperature maintained at 37 μ 0.5 ĈC. 
Samples of 5 ml were withdrawn at specific time intervals, filtered 
and analyzed at 228 nm by using UV-visible double beam 
spectrophotometer. 
Results and Discussion 
Drug-excipients compatibility study 
The FTIR spectra of pure glimepiride and physical mixture are 
shown in Figure 1 and Figure 2 respectively. The major peak of 
glimepiride in FTIR spectrum due to amide showed peak at 3367 
and 3180 cm-1, alkane in conjugation showed peak at 2860 cm-1, 
amide with para substitution showed peak at 877 cm-1. All the 
above peaks were also present in physical mixture confirming the 
presence of drug in the physical mixture without any interaction 
(Table 4). 
Evaluation of controlled porosity osmotic pump tablets 
Evaluation of powder blend 
The results of powder blend of formulations SP1 to SP8 are shown 
in Table 5.  
The results of angle of repose, bulk density, tapped density, carrÊs 
index and hausnerÊs ratio indicates that powder blend has good 
flow property with good compressibility and suitable for direct 
compression method.  
Evaluation of core tablets 
The mean value of friability, thickness, weight and content 
uniformity of prepared core tablets of glimepiride are shown in 
Table 6. 
Tablets prepared by direct compression technique showed 
uniform thickness, diameter and acceptable weight variations limit 
as per pharmacopoeial specifications.  
Hardness was found in the range of 4 to 4.5 kg/cm2 for all the 
formulations of the core tablet and the friability for all formulations 
was found to be less than 1% indicating sufficient mechanical 
integrity and strength of the prepared tablets. 
The drug content for all formulations of core tablet was performed 
in triplicate. The drug content was between 99.0 to 101.0 % which 
is within the pharmacopoeial limit i.e. 90.0 to 110.0 %.  
In vitro drug release study of factorial design 
formulations. 
The results of in vitro release of glimepiride from different factorial 
formulation SP1 to SP8 are shown in Figure 3 to 4.  
It can be evident Figure 3 to 4 that the cumulative percentage 
drug release from the formulation prepared by using 23 full 
factorial design were found to be SP1 (97.96 % in 24 h), SP2 
(94.28 % in 24 h), SP3 (96.20 % in 20 h), SP4 (94.75 % in 22 h), 
SP5 (99.90 % in 20 h), SP6 (98.48 % in 22 h), SP7 (96.00 % in 16 
h) and SP8 (92.30 % in 20 h).  
Release kinetic 
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The in vitro release profile of formulations (SP1 to SP8) was 
analyzed by various kinetic models are shown in Table 7. The 
kinetic models used were zero order, first order, higuchi and 
korsmeyer peppas equations. The release rate constants were 
calculated from the slope of the respective plots. Higher 
correlation was observed with zero order plots (r2 = 0.98-0.99) 
than first order and higuchi equation. It was observed from zero 
order plots that the drug release from controlled porosity osmotic 
pump tablets (Table 7). To find out release mechanism, the in 
vitro release data were applied in korsmeyer peppas equation. In 
the formulations under study, the value for n was found to be in 
the range of 0.85 to 1.80 (Table 7) indicating that the release 
mechanisms followed zero order case II transport and super case 
II transport as the case may be.  
Statistical analysis  
Experiments were carried out to determine the mathematical 
relationship between the factors acting on the system and the 
response of the system. The statistical evaluation of experimental 
outcomes was processed to find the optimum levels of 
drug:osmogent ratio, concentration of pore former and % weight 
gain that would provide controlled release of glimepiride form the 
formulations. A first order polynomial regression equation that 
fitted the data is as follows 
 
Y = b0 + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3 + 
b123X1X2X3 
 
Where b0 is the arithmetic mean of all the quantitative outcomes 
of the eight experimental runs, b1ăb3 are the estimated 
coefficients from the observed experimental values of Y for X1, X2, 
and X3. The interactions terms XiXjXk (i, j, and k = 1, 2, and 3) 
shows how the change in response occurs when two or more 
factors are simultaneously changed. The equation represents the 
quantitative effect of factors (X1, X2, and X3) upon the response Y.  
In the osmotic drug delivery system t90 is highly desirable 
parameter. In present study t90 was strongly influenced by % 
weight gain and composition.  
 
Y = 19.71375 - 1.58875X1- 1.31625X2 + 1.18375X3 + 0.03875 
X1X2- 19.875 X2X3+ 0.3875X1X3 + 0.0125 X1X2X3     
                                                                         
The p value of coefficients from Table 8 suggests that % weight 
gain have a significant effect on t90. The negative sign of 
coefficients of X1, X2 and the interaction terms X1X3 indicate a 
negative effect on t90. However, the coefficient values for 
interaction terms X1X2, X1X3, X2X3 and X1X2X3 shows that their 
interaction was not statistically significant (p> 0.05, Table 8), 
hence they were omitted from full model to generate the reduced 
model. The coefficients X1, X2 and X3 were found to be significant 
(p< 0.05, Table 8), hence they were retained in the reduced 
model. 
Y = 19.71375 - 1.58875X1- 1.31625X2 + 1.18375X3                                                                   
The value of R2 was found to be 0. 9990 which indicate a highly 
significant and linear relationship between X1, X2 and X3. 
 
Full and reduced model for lag time of rupture 
The full model for t90 was developed by using the coefficients. The 
significance level of coefficient β12, β23, β13 and β123 were found to 
at p > 0.05, hence it was omitted from the full model to generate 
the reduced model. The results of statistical analysis are shown in 
Table 8. The coefficients β1, β2 and β3 were found to be 
significant at p < 0.05, hence they were retained in the reduced 
model. The reduced model was tested in portions to determine 
whether the coefficient β12, β23, β13 and β123 contribute significant 
information for the prediction of t90 or not. The results for testing 
the model in portions are shown in Table 9. The critical value of F 
for đ = 0.05 is equal to 8.94 (df = 6, 3). Since the calculated value 
(F = 1.00) is less than critical value, it may be concluded that the 
interaction term β12, β23, β13 and β123 does not contribute 
significantly to the prediction of t90 and therefore can be omitted 
from the full model 
Figure 5 and 6 showed the response surface plot and Counter 
plot of durg:osmogent ratio (X1) and % weight gain (X2) versus t90 
respectively. The plot was drawn using Sigma Plot Software 11.0 
demonstration version. The data demonstrate that both X1 and X2 
affect the t90. It may also observed that the X1 and X2 appear to 
favour the preparation of controlled porosity osmotic pump tablets 
of glimepiride. It can say that the t90 may be changed by 
appropriate selection of the X1 and X2 levels. The area in counter 
plot (Figure 6) shows if we selected X1 and X2 in this range we get 
the desired release profile of glimepiride tablet. 
Validation of statistical model 
Further optimization was carried out using grid search technique 
keeping X2 as constant (level 1). The formulations whose 
response has optimal characteristics based on the experimenterÊs 
specifications can then be chosen. It clearly evident that X1, X2 
and X3 give desired response. Formulation SP9 was formulated 
by using -1 (1:1.25 drug:osmogent), -1(10% w/w) and -0.85 
(6.8%) as X1, X2 and X3. Formulation SP9 was optimized 
formulation that was used for further study. The optimized 
formulation SP9 was prepared on the basis of lay out grid search 
technique the composition is shown in Table 3. 
In vitro dissolution study of optimized formulation 
The results of in vitro release of glimepiride from optimized 
formulation are shown in Figure 7. It evident that the selection of 
the optimized formulation on the basis of grid search technique 
and preparation of the optimized formulation on the basis of it 
gave us the desired results in terms of time for 90% drug release 
(21.61 h). 
From the results of dissolution profile of check point formulations 
SP9 (Figure 7), it was concluded that there is no significant 
difference in experimental t90 than that of predictable one (Table 
10). 
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To study effect of pH on in vitro drug release 
The results of in vitro release of glimepiride from optimized 
formulation SP9 are shown in Figure 8.  
It suggest that the dissolution data and dissolution profile of 
optimize formulation SP9 in pH 1.2 hydrochloric acid, pH 6.8 
phosphate buffer and pH 7.4 phosphate buffer solutions 
respectively. The drug release rate in different dissolution media 
was almost similar. The pH of dissolution media has not 
significant impact on the drug release. So, the drug release from 
controlled porosity osmotic pump tablet was independent on pH.  
To study effect of agitation intensity on in vitro drug 
release  
The results of in vitro release of glimepiride from optimized 
formulation SP9 are shown in Figure 9. It clearly evident that the 
dissolution data and dissolution profile of optimize formulation at 
50 rpm, 100 rpm and 150 rpm. The drug release rate at different 
agitation speed was almost similar. The agitation speed of paddle 
has not significant impact on the drug release. So, the drug 
release from controlled porosity osmotic pump tablet was 
independent on agitation intensity. It could be expected that the 
release from the developed formulation will be independent of the 
hydrodynamic condition of the body. 
Conclusion 
Glimepiride was successfully formulated as controlled porosity 
osmotic pump tablets to release drug up to 24 h. The rate of drug 
release from the formulation increased with increased 
concentration of osmogent or pore former. The optimized 
formulation displayed desired results in terms of time for 90% 
drug release (t90) for 21.61 h and mimicking the fluctuating 
symptoms of diabetes. 
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Table 1 Selection of levels for independent variables 
Levels X1 
(Drug:osmogent ratio) 
X2 
(Concentration of pore former) 
X3 
(% wt gain) 
Low  
(-1)  
1:1.25 10% w/w 8% 
High 
(+1) 
1:3.75 20% w/w 10% 
 
 
 
 
 
 
Table 2 Composition of factorial design formulations for controlled porosity osmotic pump tablets 
Core tablets 
Ingredients  (mg) SP1 SP2 SP3 SP4 SP5 SP6 SP7 SP8 
Glimepiride 4 4 4 4 4 4 4 4 
NaCl 5 5 5 5 15 15 15 15 
Lactose 63 63 63 63 63 63 63 63 
MCC 25 25 25 25 15 15 15 15 
Mg. Stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Talc 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Total weight 100 100 100 100 100 100 100 100 
Coating solution 
Cellulose acetate (% 
w/v ) 
4 4 4 4 4 4 4 4 
PEG 400 
(% w/w of dry 
polymer) 
10 
 
 
10 20 20 10 10 20 20 
Sudan red q.s q.s q.s q.s q.s q.s q.s q.s 
Acetone q.s q.s q.s q.s q.s q.s q.s q.s 
% wt gain 8 10 8 10 8 10 8 10 
Total weight 108 110 108 110 108 110 108 110 
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Table 3 Composition of controlled porosity osmotic pump tablets of optimized formulation SP9 
Core tablets 
Ingredients (mg) SP9 
Glimepiride 4 
NaCl 5 
Lactose 63 
MCC 25 
Mg Stearate 1.5 
Talc 1.5 
Total weight 100 
Coating 
Cellulose acetate (% w/v ) 4 
PEG 400(% w/w of dry polymer) 10 
Sudan red q.s 
Acetone q.s 
% weight gain 6.8 
Total weight 106.8 
 
 
Table 4 FTIR interpretation data of glimepiride and physical mixture 
            FTIR peak at cm-1  Interpretation 
Glimepiride Physical mixture
3367, 3180 3300-3500 Primary  amide stretching (2bands) 
2860 2850 -C-H stretching alkane 
1680-1630 1684 -C=O stretching 
877 876 Amide with para substitution 
 
Table 5 Evaluation of powder blend 
Formulation 
code 
Bulk 
density* 
(gm/ml) 
Tapped 
density* 
(gm/ml) 
Hausner’s 
ratio* 
Carr’s 
Index* (%) 
Angle 
of repose 
( ° ) 
SP1 0.220±0.020 0.250±0.025 1.14 ± 0.026 12.59 ± 0.40 24.18 
SP2 0.271±0.002 0.321±0.005 1.18 ± 0.025 15.26 ± 0.57 26.45 
SP3 0.293±0.015 0.352±0.017 1.20 ± 0.023 16.54 ± 0.33 23.57 
SP4 0.225±0.020 0.256±0.029 1.14 ± 0.026 12.10 ± 0.44 28.28 
SP5 0.270±0.002 0.322±0.010 1.19 ± 0.025 16.14 ± 0.57 26.30 
SP6 0.257±0.015 0.301±0.015 1.17 ± 0.023 14.61 ± 0.39 25.34 
SP7 0.246±0.015 0.298±0.027 1.21 ± 0.023 17.44 ± 0.43 27.90 
SP8 0.228±0.020 0.259±0.015 1.14 ± 0.026 11.96 ± 0.42 26.11 
* Values are mean μ SD, (n=3) 
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Table 6 Evaluation of core tablets 
Formulation 
code 
Diameter* 
(mm ) 
Weight 
variation 
Thickness* 
(mm ) 
Hardness* 
(kg/ cm²) 
% Friability Content 
uniformity* 
(%) 
SP1 6.36± 0.01 Pass 2.25± 0.27 4±0.19 0.3976 99.51±0.25 
SP2 6.36± 0.01 Pass 2.23± 0.35 4±0.47 0.3952 98.19±0.29 
SP3 6.36± 0.01 Pass 2.19± 0.25 4±0.28 0.4955 99.11±0.34 
SP4 6.36± 0.01 Pass 2.21± 0.27 4±0.19 0.3456 99.59±0.25 
SP5 6.36± 0.01 Pass 2.14± 0.35 4±0.47 0.3842 98.49±0.29 
SP6 6.36± 0.01 Pass 2.18± 0.25 4±0.28 0.4165 98.51±0.34 
SP7 6.36± 0.01 Pass 2.24± 0.27 4±0.19 0.3878 99.54±0.25 
SP8 6.36± 0.01 Pass 2.29± 0.35 4±0.47 0.3459 98.29±0.29 
* Values are mean ± SD, (n=3) 
 
Table 7 Drug release kinetic data of formulation SP1 to SP8 
Formulation  Regression coefficient (R) 
Zero order  First order  Higuchi  Krosmayer‐ 
peppas 
K0  r
2  K1  r
2  Kh  r
2  n  r2 
SP1  4.37  0.989  0.14  0.817  19.46  0.992  1.18  0.935 
SP2  4.13  0.993  016  0.787  25.05  0.991  1.64  0.953 
SP3  4.95  0.993  0.14  0.714  27.12  0.978  1.11  0.945 
SP4  4.35  0.995  0.13  0.870  24.73  0.969  1.33  0.943 
SP5  4.77  0.982  0.11  0.876  26.60  0.994  0.85  0.966 
SP6  4.40  0.982  0.09  0.836  25.96  0.993  0.98  0.959 
SP7  5.50  0.998  0.09  0.924  27.32  0.981  0.79  0.991 
SP8  4.74  0.995  0.11  0.818  25.42  0.984  0.83  0.986 
K: release rate constant, r2: coefficient of determination, n: release exponent 
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Table 8 Regression Statistics for Y 
Regression Statistics  for Y 
Multiple R 0.995371 
R Square 0.990763 
Adjusted R Square 0.983836 
Standard Error 0.324788 
Observations 8 
Coefficients P-value 
β0 = 19.71375 6.90E-09 
β1 = -1.58875 0.000158 
β2 = -1.31625 0.000330 
β3 = 1.18375 0.000499 
β12= 0.038 0.31 
β13= -19875 1.12566 
β23= 0.3875 0.067809 
β123 = 0.02125 0.98 
 
 
Table 9 Calculations for testing the model in portions 
t90 
 DF SS MS F R2  
Regression   
FM 7 45.6815 7.6135 210.75 0.9992 Fcal  = 1.00 
 
Fcri = 8.94 
 
DF = (6,3) 
RM 3 45.2632 15.087 143.02 0.990 
Error  
FM 1 0.0036 0.0036 - - 
RM 4 0.4220 0.105 - - 
DF: degree of freedom, SS: sum of squares, MS: mean of squares, F: Fischer’s ratio, R2: regression 
coefficient, FM: full model, RM: reduced model. 
 
 
Table 10 The experimental and predicted values for responses Y  
Formulation code t90 (h) 
Experimental value Predicted value % Bias 
SP9 21.68 21.61 0.3228 
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Figure 1 FTIR Spectra of glimepiride 
 
Figure 2 FTIR spectra of physical mixture 
 
Figure 3 In vitro release of glimepiride from the SP1 to SP4 formulations 
 
Figure 4 In vitro release of glimepiride from the SP5 to SP8 formulations 
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Figure 5 Response surface plot showing the influence of % weight gain and drug:osmogent 
ratio on response Y i.e. t90. 
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Figure 6 Contour plot showing relationship between drug:osmogent ratio and % weight gain on t90 
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Figure 7 In vitro release of glimepiride from SP9 formulation 
 
 
Figure 8 In vitro release of glimepiride from SP9 formulation in 0.1 N HCl, phosphate buffer pH 6.8 
and phosphate buffer pH 7.4 
 
 
 
Figure 9 In vitro release of glimepiride from SP9 formulation at 50 rpm, 100 rpm and 150 rpm 
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